Science & Technology
Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease
Department of Health and Human Services — National Institutes of Health
Opportunity #: 2R44NS120360-03
Award Ceiling
$1.2M
Award Floor
$1.2M
Close Date
Jun 30, 2027
472 days leftTotal Funding
$1.2M
Expected Awards
1
Posted Date
Aug 22, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-2R44NS120360-03
Description
SBIR Phase Phase II award: "Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease" awarded to Circumvent Pharmaceuticals in Portland, Oregon. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,244,790. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.